Dual neutralization of IL-17A and IL-17F with bimekizumab improves quality of life in patients withmoderate-to-severe plaque psoriasis: results from a Phase 2b study and correlation with clinical response. (2018). SKIN The Journal of Cutaneous Medicine, 2, S92. https://doi.org/10.25251/skin.2.supp.93